Preparation method of T2 contrast agent based on minimum superparamagnetic ferroferric oxide nanoparticles

Superparamagnetic iron tetraoxide nanoparticles prepared by variable temperature-speed high-temperature pyrolysis method and ligand exchange method solve the problem of nanoparticles preparation in the prior art size less than 5nm, significantly improving the development sensitivity and nanoparticles of T2 imaging Penetration ability.

CN118903482APending Publication Date: 2024-11-08ZHEJIANG UNIV
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411021886.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-07-29
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

There is no method in the prior art to prepare tri-ferromagnetic nanoparticles with a size less than 5 nm to behave as superparamagnetic, resulting in insufficient development sensitivity of T2-weighted imaging, and the existing superparamagnetic nanoparticles are large in size and are not conducive to tumors. Penetration in tissue.

Method used

The oil-phase superparamagnetic ferrous oxide nanoparticles are prepared by high-temperature pyrolysis method with variable temperature speed, and converted into the aqueous superparamagnetic ferrous oxide nanoparticles through ligand exchange method. The specific steps include magnetic force Mix under stirring, control the heating rate and insulation time, perform multiple centrifugal washing and ultrasonic dispersion to ensure the monodispersibility and crystal structure of the nanoparticles.

Benefits of technology

The development sensitivity of T2 imaging is significantly improved, the saturation magnetization of nanoparticles reaches 39emu/g, the lateral relaxation rate is increased by 11.3 times, and the particle size is less than 10nm, which is suitable for penetration in tumor tissue.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118903482A_ABST
    Figure CN118903482A_ABST
Patent Text Reader

Abstract

The invention discloses a preparation method of a T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles, which comprises the following steps: preparing oil-phase superparamagnetic ferroferric oxide nanoparticles by adopting a variable-temperature-rate high-temperature pyrolysis method, preparing water-phase superparamagnetic ferroferric oxide nanoparticles by adopting a ligand exchange method based on the oil-phase nanoparticles, and preparing the T2 contrast agent based on the extremely small superparamagnetic ferroferric oxide nanoparticles. And the contrast agent is used as a T2 contrast agent. The T2 contrast agent prepared by the method disclosed by the invention realizes high-sensitivity T2 weighted imaging of 4nm superparamagnetic ferroferric oxide nanoparticles, is beneficial to improving the penetrating power of the contrast agent in tumor tissues, and has a wide application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to magnetic particle imaging technology and the field of inorganic material preparation, and in particular to a method for preparing a T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles. Background Art

[0002] Magnetic Resonance Imaging (MRI), as an advanced medical imaging technology based on the principle of nuclear magnetic resonance, has greatly promoted the development of medicine and cognitive neuroscience by its application in the field of imaging of internal tissue structures of the human body. Compared with other medical imaging technologies, MRI has many advantages, including excellent soft tissue imaging capabilities, a wide detection range, and no ionizing radiation. Traditional MRI technology mainly relies on the subtle differences in the relaxation time of hydrogen protons in normal human tissue and diseased tissue for imaging. However, in the early stages of the lesion, this difference is often very small, so it is difficult to accurately identify the diseased tissue based solely on the hydrogen protons in the tissue. In order to improve the sensitivity of MRI technology, contrast enhancement agents are usually introduced to enhance image contrast, so as to more accurately identify diseased tissue.

[0003] As contrast agents, ferroferric oxide magnetic nanoparticles are widely used in the field of magnetic resonance imaging due to their rapid magnetic response and excellent biocompatibility. At present, according to the size range of ferroferric oxide magnetic nanoparticles, they can be used as contrast agents for longitudinal relaxation (T1) and transverse relaxation (T2) imaging enhancement modes. Among them, when the size of ferroferric oxide magnetic nanoparticles is greater than or equal to 6nm, that is, conventional-scale ferroferric oxide magnetic nanoparticles, they exhibit superparamagnetism and are therefore usually used as T2 contrast agents. At extremely small sizes (less than 6nm), due to the increase in the proportion of the magnetic dead layer at the interface of the nanoparticles, their magnetic properties are transformed into paramagnetism, so they are usually used as T1 contrast agents. For example, the 4nm ferroferric oxide magnetic nanoparticles currently prepared by the existing high-temperature pyrolysis method with a constant temperature rate mostly exhibit paramagnetism and are usually used as T1 contrast agents. At present, there is no extremely small ferroferric oxide magnetic nanoparticle with a size less than 5nm that exhibits superparamagnetism and is used as a T2-weighted contrast agent.

[0004] Since the size of existing superparamagnetic ferroferric oxide magnetic nanoparticles is greater than or equal to 6 nm, this size is not conducive to the penetration of contrast agents in tumor tissues. So far, there is still no method for preparing superparamagnetic ferroferric oxide magnetic nanoparticles with a size less than 5 nm. Summary of the invention

[0005] In view of the shortcomings of the prior art, the present invention proposes a method for preparing a T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles, which can significantly improve the imaging sensitivity of T2 weighted imaging.

[0006] The specific technical solutions are as follows:

[0007] A method for preparing a T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles, firstly adopting a variable temperature high temperature pyrolysis method to prepare oil-phase superparamagnetic ferroferric oxide nanoparticles OA@Fe3O4, and then adopting a ligand exchange method to use OA@Fe3O4 to prepare water-phase superparamagnetic ferroferric oxide nanoparticles DHCA@Fe3O4, i.e., a T2 contrast agent; specifically comprising the following steps:

[0008] S1: dissolving ferric acetylacetonate, oleic acid, oleylamine, and 1,2-hexadecanediol in a reducing solvent at a molar ratio of 1:3:3:5 to 1:4:4:7, and mixing them uniformly under magnetic stirring;

[0009] Among them, adjusting the content of oleic acid and oleylamine is beneficial to controlling the growth rate and improving the monodispersity of the product. 1,2-hexadecanediol is used as a reducing agent, and regulating its content is beneficial to regulating the reduction reaction; if it is less than the molar ratio range, it cannot react fully; if it is greater than the molar ratio range, it will cause waste of reagents and increase costs.

[0010] S2: evacuate the mixed solution obtained in S1 at room temperature, heat it to 60-90° C., and evacuate it again; S2 is performed under magnetic stirring;

[0011] S3: turn off the vacuum, fill with nitrogen, and heat the mixed solution obtained in S2 to 150-220°C at a rate of 0.5-2.5°C / min under a nitrogen atmosphere, and keep it warm for 20-120min; then heat it to 250-300°C at a rate of 3-10°C / min, and keep it warm for 20-60min; S3 is performed under magnetic stirring;

[0012] Optimizing the heating rate is beneficial to controlling the particle nucleation size, improving particle uniformity, and regulating particle crystallinity and crystal face parameters. During the first heating, if the heating rate is less than 0.5℃ / min, the nucleation process will be too slow, and it is easy to form overly large nanoparticles. It may also cause the particles to agglomerate during the growth process, thereby forming larger aggregates; if the heating rate is greater than 2.5℃ / min, the crystal nucleus will form rapidly, resulting in more crystal structure defects, larger crystal face parameters, and lower crystallinity. Correspondingly, if the heating temperature is less than 150℃ or greater than 220℃, the nucleation rate of the grains will be inconsistent, resulting in a wider size distribution. Correspondingly, if the holding time is less than 20min, the crystal nucleus growth time will be insufficient, and the crystal nucleus size will vary greatly; if the holding time exceeds 120min, the crystal nucleus will grow excessively and dissolve, which will also cause large differences in the crystal nucleus size.

[0013] During the second heating, if the heating rate is less than 3℃ / min, the nucleus growth rate will be too slow, and larger nanoparticles will be easily formed; if the heating rate is greater than 10℃ / min, the nucleus growth rate will be too fast, the growth will be insufficient, and a wider size distribution and low crystallinity will be formed. Correspondingly, if the heating temperature is lower than 250℃, the reflux process will be insufficient, and then the nucleus growth will be insufficient, forming a wider size distribution; if it is higher than 300℃, the reaction solvent will reflux too fast, resulting in the loss of reactants, and also insufficient nucleus growth. Correspondingly, if the insulation time is less than 20min, the sufficient nucleus growth process cannot be guaranteed, resulting in the formation of a large number of smaller particles; if the insulation time is higher than 60min, the nucleus will grow excessively and be accompanied by partial dissolution, forming larger particles, and it is easy to increase the anisotropy of the particle shape.

[0014] S4: Cool the reactants obtained in S3 to room temperature and dispense them into centrifuge tubes; add ethanol or acetone into the centrifuge tubes to wash the free surfactant after centrifugation; after centrifugation, remove the supernatant and take the precipitate in the tube; add a base carrier liquid into the centrifuge tube to dissolve the precipitate, centrifuge again, and pour the obtained supernatant into a new centrifuge tube;

[0015] S5: Repeat the centrifugal washing process of S4 for multiple times to obtain superparamagnetic iron oxide nanoparticles OA@Fe3O4 in the oil phase, and disperse them in a tetrahydrofuran (THF) solution;

[0016] S6: Using the OA@Fe3O4, a ligand exchange method is used to prepare aqueous superparamagnetic ferrosoferric oxide nanoparticles DHCA@Fe3O4, i.e., a T2 contrast agent.

[0017] Furthermore, the S6 is specifically implemented through the following sub-steps:

[0018] S6.1: Dissolve DHCA in THF to obtain a mixed solution, heat the mixed solution in an oil bath to 40-60°C; take the THF solution of OA@Fe3O4 obtained in S5, add it dropwise to the mixed solution to make the mass ratio of DHCA to OA@Fe3O4 be 1:1-5:1, and keep it warm for more than 2 hours; S6.1 is performed under magnetic stirring to make DHCA and OA@Fe3O4 mix and react more evenly;

[0019] If the temperature after heating is lower than 40°C, the reflux will be insufficient; if the temperature is higher than 60°C, the reactants will volatilize and be lost. When DHCA and OA@Fe3O4 are mixed and reacted, the increase of DHCA content is conducive to improving the reaction rate. If the mass ratio of DHCA to OA@Fe3O4 is too low, the reaction will be incomplete; if the mass ratio is too high, the cost will increase. In the subsequent insulation, if the insulation time is less than 2h, the reaction will be incomplete; if it is greater than 6h, the time cost will increase.

[0020] S6.2: The reactants obtained in S6.1 are cooled to room temperature and divided into centrifuge tubes; NaOH solution is added to the centrifuge tubes to make the mixed solution weakly alkaline; after centrifugation, the supernatant is removed and the precipitate in the tube is taken; deionized water is added to the centrifuge tubes to dissolve the precipitate, and then ultrasonically dispersed to obtain aqueous superparamagnetic ferroferric oxide nanoparticles DHCA@Fe3O4.

[0021] Furthermore, in S1, the reducing solvent includes any one of diphenyl ether, dibenzyl ether, and octadecene.

[0022] Furthermore, in S4, the base carrier liquid includes any one of cyclohexane, dichloromethane, chloroform and toluene.

[0023] Further, in S4, the volume ratio of ethanol to reactant in the centrifuge tube is 3:2 to 5:2, and the volume ratio of acetone to reactant is 3:2 to 5:2. The increase of ethanol or acetone is beneficial to the cleaning of free surfactant, but excessive ethanol or acetone will cause unnecessary waste.

[0024] Preferably, in S1, the molar ratio of ferric acetylacetonate, oleic acid, oleylamine and 1,2-hexadecanediol is 1:3.5:3.5:6.

[0025] Preferably, in S2, the mixed solution is vacuumed at room temperature for 10 to 120 minutes, heated to 60 to 90°C, and then vacuumed for 10 to 120 minutes. Generally, a 10-minute room temperature vacuum operation can achieve the minimum vacuum requirement (i.e., if it is less than 10 minutes, the vacuum does not meet the reaction requirements). As the vacuum time increases, the content of water, air, etc. in the mixed solution is further reduced. Therefore, a vacuum time within the range of 10 to 120 minutes is conducive to the formation of a high-crystallinity product, but a too long time (greater than 120 minutes) has little effect on improving the vacuum, but increases the time cost. The time range for vacuuming after heating is 10 to 120 minutes. A temperature below 60°C is not conducive to removing water, air, etc. that are still dissolved in the mixed solution at room temperature, and a temperature above 90°C will cause the mixed solution to partially volatilize, resulting in an imbalance in proportion and insufficient reaction.

[0026] Preferably, in S3, the mixed liquid is heated to 180-200°C at a rate of 2-2.5°C / min under a nitrogen atmosphere, and kept warm for 30-60 min; then heated to 265-275°C at a rate of 3-5°C / min, and kept warm for 30-45 min.

[0027] Preferably, in S4, after centrifugation at a speed of 5000-8500 rpm / min for 10-20 min, the precipitate is collected; after adding a base carrier liquid to dissolve the precipitate, the supernatant is collected after centrifugation at a speed of 5000-8500 rpm / min for 10-20 min.

[0028] During the first centrifugation, if the centrifugal speed is lower than 5000rpm / min, only larger particles are allowed to precipitate, resulting in insufficient precipitation of the target product and unnecessary waste; if the speed is higher than 8500rpm / min, a large number of small particles and organic matter that have not reacted completely cannot be separated, resulting in a wide size distribution. Accordingly, if the centrifugal time is less than 10min, the product has not been completely separated, resulting in unnecessary loss; if the centrifugal time is greater than 20min, it will increase the time cost.

[0029] During the second centrifugation, if the centrifugal speed is lower than 5000rpm / min, the small particles in the supernatant cannot be removed; if the centrifugal speed is higher than 8500rpm / min, some products will precipitate out of the supernatant, causing loss. Correspondingly, if the centrifugal time is less than 10min, the centrifugal process will be incomplete and impurities will not be completely separated; if the centrifugal time is greater than 20min, unnecessary time costs will be added.

[0030] Preferably, in S6.1, the mixed solution is heated to 40-60°C; the DHCA and OA@Fe3O4 are kept warm for 2-6 hours after mixing;

[0031] In the S6.2, the concentration of NaOH is 0.3-0.6 mol / L, and the NaOH solution of this concentration can make the added NaOH solution alkaline within the capacity range of the centrifuge tube; during centrifugation, centrifuge at a speed of 2000-4000 rpm / min for 10-20 min; the ultrasonic dispersion time is 10-60 min. During centrifugation, if the centrifugal speed is lower than 2000 rpm / min, the target product cannot be completely precipitated, resulting in loss; if the centrifugal speed is higher than 4000 rpm / min, some impurities and the target product will be precipitated and cannot be separated. Correspondingly, if the centrifugal time is less than 10 min, the centrifugal process will be insufficient, the target product will not be completely precipitated, resulting in loss; if the centrifugal time is greater than 20 min, the time cost will increase. In the subsequent ultrasonic dispersion operation, if the ultrasonic time is too short, the dissolution will be incomplete, and if it is too long, the time cost will increase.

[0032] A T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles is prepared according to the preparation method of the T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles.

[0033] The beneficial effects of the present invention are:

[0034] (1) The superparamagnetic iron oxide nanoparticles (SPIONs) contrast agent of the present invention has a high saturation magnetization intensity of 39emu / g and a transverse relaxation rate (r2) of 201.8mM. -1 s -1 It is 11.3 times higher than the paramagnetic iron oxide nanoparticles (PIONs) contrast agent of the same size, significantly improving the sensitivity of T2 imaging.

[0035] (2) The superparamagnetic ferroferric oxide nanoparticle contrast agent of the present invention has an extremely small particle size and a small hydrodynamic diameter of about 5 to 9 nm and good monodispersity. This particle size is conducive to the penetration of the contrast agent in tumor tissue. BRIEF DESCRIPTION OF THE DRAWINGS

[0036] Figure 1 This is the TEM image of OA@Fe3O4 prepared in Example 1 of the present invention.

[0037] Figure 2This is a particle size diagram of OA@Fe3O4 prepared in Example 1 of the present invention.

[0038] Figure 3 This is the X-ray diffraction pattern of OA@Fe3O4 prepared in Example 1 of the present invention.

[0039] Figure 4 This is the hysteresis loop of the 4 nm SPIONs contrast agent prepared in Example 1 of the present invention at room temperature.

[0040] Figure 5 This is the hysteresis loop of the 4 nm SPIONs contrast agent prepared in Example 1 of the present invention at 5K.

[0041] Figure 6 This is the temperature-dependent magnetization curve of the 4 nm SPIONs contrast agent prepared in Example 1 of the present invention.

[0042] Figure 7 This is the hydrodynamic particle size diagram of 4 nm SPIONs prepared in Example 1 of the present invention.

[0043] Figure 8 This is a TEM image of the oil-phase PIONs prepared in the comparative example of the present invention.

[0044] Fig. 9 This is a particle size diagram of the oil phase PIONs prepared in the comparative example of the present invention.

[0045] Fig.10 This is the X-ray diffraction pattern of the oil phase PIONs prepared in the comparative example of the present invention.

[0046] Fig.11 This is a hydrodynamic particle size diagram of aqueous phase PIONs prepared in comparative example of the present invention.

[0047] Fig.12 This is the hysteresis loop of the 4 nm PIONs contrast agent prepared in the comparative example of the present invention at room temperature.

[0048] Fig.13 This is the hysteresis loop of the 4 nm PIONs contrast agent prepared in the comparative example of the present invention at 5K.

[0049] Fig.14 This is a T2 imaging comparison diagram of the 4 nm SPIONs contrast agent prepared in Example 1 of the present invention and the 4 nm PIONs contrast agent prepared in the comparative example.

[0050] Fig.15 This is a comparison chart of the R2 relaxation rates of the 4 nm SPIONs contrast agent prepared in Example 1 of the present invention and the 4 nm PIONs contrast agent prepared in the comparative example. DETAILED DESCRIPTION

[0051] The present invention will be described in detail below according to the accompanying drawings and preferred embodiments, and the purpose and effect of the present invention will become more clear. The present invention will be further described in detail below in conjunction with the accompanying drawings and embodiments. It should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the present invention.

[0052] Example 1

[0053] A method for preparing a T2 contrast agent based on 4nm superparamagnetic ferroferric oxide nanoparticles (SPIONs), specifically comprising the following steps:

[0054] Firstly, 4nm superparamagnetic iron oxide nanoparticles OA@Fe3O4 in oil phase were prepared by high temperature pyrolysis method with variable temperature rate.

[0055] S1: Ferrous acetylacetonate, oleic acid, oleylamine, and 1,2-hexadecanediol were dissolved in diphenyl ether at a molar ratio of 1:3.5:3.5:6, and mixed evenly under magnetic stirring.

[0056] S2: The mixed solution obtained in S1 is evacuated at room temperature for 30 minutes, heated to 80°C, and then evacuated for another 30 minutes; S2 is performed under magnetic stirring.

[0057] S3: turn off the vacuum, fill with nitrogen, and heat the mixed solution obtained in S2 to 200°C at a rate of 2.5°C / min under a nitrogen atmosphere, and keep it warm for 30 minutes; then heat it to 265°C at a rate of 3°C / min, and keep it warm for 30 minutes; S3 is performed under magnetic stirring.

[0058] S4: The reactants obtained in S3 were cooled to room temperature and divided into centrifuge tubes; ethanol was added to the centrifuge tubes to wash the free surfactant after centrifugation; the volume ratio of ethanol to reactants was 2:1. After centrifugation at 6000 rpm / min for 15 min, the supernatant was removed and the precipitate in the tube was taken; an appropriate amount of cyclohexane was added to the centrifuge tube to dissolve the precipitate, and the supernatant was poured into a new centrifuge tube after centrifugation at 6000 rpm / min for 15 min.

[0059] S5: Repeat the centrifugal washing process of S4 for 3 times to obtain superparamagnetic iron oxide nanoparticles OA@Fe3O4 in the oil phase, and disperse them in a THF solution. The amount of THF is selected according to the required concentration of the OA@Fe3O4 THF solution, and the minimum requirement is to completely dissolve OA@Fe3O4. The obtained OA@Fe3O4 THF solution can be placed in a refrigerator for refrigeration.

[0060] The morphology of OA@Fe3O4 prepared in this example is as follows Figure 1 As shown by Figure 1It can be seen that the nanoparticles are spherical and evenly dispersed. Figure 2 As shown in Figure 2, the average particle size of the nanoparticles is 4.01±0.3 nm. The crystal structure of the nanoparticles is shown in Figure 2 Figure 3 As shown, it is an inverse spinel structure. Figure 1-Figure 3 , proving that the nanoparticles are 4nm ferroferric oxide.

[0061] S6: Using OA@Fe3O4, a ligand exchange method is used to prepare 4nm superparamagnetic ferroferric oxide nanoparticles DHCA@Fe3O4 in the aqueous phase, which can be used as a 4nm SPIONs contrast agent for T2. The specific steps include the following:

[0062] S6.1: Dissolve DHCA in THF to obtain a mixed solution, and heat the mixed solution in an oil bath to 50°C; Take the THF solution of OA@Fe3O4 obtained in S5, add it dropwise to the mixed solution to make the mass ratio of DHCA to OA@Fe3O4 to 3:1, and keep it warm for 6 hours; S6.1 is performed under magnetic stirring to make DHCA and OA@Fe3O4 mix and react more evenly.

[0063] S6.2: The reactants obtained in S6.1 were cooled to room temperature and divided into centrifuge tubes; a small amount of 0.5 mol / L NaOH solution was added to the centrifuge tubes to make the mixed solution weakly alkaline. Then, after centrifugation at a speed of 4000 rpm / min for 20 min, the supernatant was removed and the precipitate in the tube was taken; deionized water was added to the centrifuge tube to dissolve the precipitate, and then ultrasonically dispersed for 30 min to obtain aqueous superparamagnetic ferroferric oxide nanoparticles DHCA@Fe3O4. The obtained DHCA@Fe3O4 aqueous solution can be placed in a refrigerator at 4°C.

[0064] The hysteresis loop of the nanoparticles at room temperature is as follows Figure 4 As shown by Figure 4 It can be seen that the magnetization intensity of the nanoparticles gradually increases with the increase of the magnetic field and tends to saturation at high fields, with a saturation magnetization intensity as high as 39emu / g; the hysteresis loop of the nanoparticles at 5K is shown in Figure 5 As shown by Figure 5 It can be seen that the nanoparticles have coercivity and remanence, showing obvious ferromagnetism. The temperature-dependent magnetization curve of the nanoparticles is shown in Figure 6 As shown in the figure, the magnetization intensity in the field cooling curve (FC) gradually decreases with increasing temperature, and the magnetization intensity in the zero magnetic field cooling curve (ZFC) first increases and then decreases with increasing temperature. The temperature 37K corresponding to the peak of the curve is the blocking temperature. The hydrodynamic particle size of the nanoparticle is shown in Figure 7As shown, it is 5.8±0.5nm. Figure 4-Figure 7 , indicating that the DHCA@Fe3O4 nanoparticles (i.e., 4 nm SPIONs contrast agent) prepared in this example have typical superparamagnetism.

[0065] Example 2

[0066] A method for preparing a T2 contrast agent based on 4nm superparamagnetic ferroferric oxide nanoparticles, specifically comprising the following steps:

[0067] Firstly, 4nm superparamagnetic iron oxide nanoparticles OA@Fe3O4 in oil phase were prepared by high temperature pyrolysis method with variable temperature rate.

[0068] S1: Ferrous acetylacetonate, oleic acid, oleylamine, and 1,2-hexadecanediol were dissolved in dibenzyl ether at a molar ratio of 1:4:4:7, and mixed evenly under magnetic stirring.

[0069] S2: The mixed solution obtained in S1 is evacuated at room temperature for 60 min, heated to 90°C, and then evacuated for another 60 min; S2 is performed under magnetic stirring.

[0070] S3: turn off the vacuum, fill with nitrogen, and heat the mixed liquid obtained in S2 to 180°C at a rate of 2.5°C / min under a nitrogen atmosphere, and keep it warm for 60 minutes; then heat it to 300°C at a rate of 5°C / min, and keep it warm for 45 minutes; S3 is performed under magnetic stirring.

[0071] S4: Cool the reactants obtained in S3 to room temperature and dispense them into centrifuge tubes; add acetone into the centrifuge tubes, with the volume ratio of acetone to reactants being 5:2. Centrifuge at 8000 rpm / min for 15 min, remove the supernatant, and take the precipitate in the tube; add an appropriate amount of dichloromethane into the centrifuge tube to dissolve the precipitate, centrifuge again at 8000 rpm / min for 15 min, and pour the supernatant into a new centrifuge tube.

[0072] S5: Repeat the centrifugal washing process of S4 for 3 times to obtain superparamagnetic iron oxide nanoparticles OA@Fe3O4 in the oil phase, and disperse them in a THF solution. The obtained OA@Fe3O4 THF solution can be placed in a refrigerator for refrigeration.

[0073] S6: Using OA@Fe3O4, a ligand exchange method is used to prepare 4nm superparamagnetic ferroferric oxide nanoparticles DHCA@Fe3O4 in the aqueous phase, which can be used as a 4nm SPIONs contrast agent for T2. The specific steps include the following:

[0074] S6.1: Dissolve DHCA in THF to obtain a mixed solution, heat the mixed solution in an oil bath to 50°C; take the THF solution of OA@Fe3O4 obtained in S5, add it dropwise to the mixed solution to make the mass ratio of DHCA to OA@Fe3O4 be 4:1, and keep warm for 5 hours; S6.1 is performed under magnetic stirring.

[0075] S6.2: The reactants obtained in S6.1 were cooled to room temperature and divided into centrifuge tubes; a small amount of 0.4 mol / L NaOH solution was added to the centrifuge tubes to make the mixed solution weakly alkaline. Then, the mixture was centrifuged at 4000 rpm / min for 15 min, the supernatant was removed, and the precipitate in the tube was taken; deionized water was added to the centrifuge tubes to dissolve the precipitate, and then ultrasonically dispersed for 10 min to obtain aqueous superparamagnetic ferroferric oxide nanoparticles DHCA@Fe3O4, which can be placed in a refrigerator at 4°C.

[0076] Example 3

[0077] A method for preparing a T2 contrast agent based on 4nm superparamagnetic ferroferric oxide nanoparticles, specifically comprising the following steps:

[0078] Firstly, 4nm superparamagnetic iron oxide nanoparticles OA@Fe3O4 in oil phase were prepared by high temperature pyrolysis method with variable temperature rate.

[0079] S1: Ferrous acetylacetonate, oleic acid, oleylamine, and 1,2-hexadecanediol were dissolved in octadecene at a molar ratio of 1:3:3:5, and mixed evenly under magnetic stirring.

[0080] S2: The mixed solution obtained in S1 is evacuated at room temperature for 10 min, heated to 60°C, and then evacuated for another 120 min; S2 is performed under magnetic stirring.

[0081] S3: turn off the vacuum and fill with nitrogen, so that the mixed liquid obtained in S2 is heated to 220°C at a rate of 2°C / min under a nitrogen atmosphere and kept warm for 20 minutes; then heated to 280°C at a rate of 10°C / min and kept warm for 60 minutes; S3 is performed under magnetic stirring.

[0082] S4: Cool the reactants obtained in S3 to room temperature and dispense them into centrifuge tubes; add ethanol to the centrifuge tubes, with the volume ratio of ethanol to reactants being 3:2. Centrifuge at 5000 rpm / min for 20 min, remove the supernatant, and take the precipitate in the tube; add an appropriate amount of chloroform to the centrifuge tube to dissolve the precipitate, centrifuge again at 5000 rpm / min for 20 min, and pour the supernatant into a new centrifuge tube.

[0083] S5: Repeat the centrifugal washing process of S4 for 3 times to obtain superparamagnetic iron oxide nanoparticles OA@Fe3O4 in the oil phase, and disperse them in a THF solution. The obtained OA@Fe3O4 THF solution can be placed in a refrigerator for refrigeration.

[0084] S6: Using OA@Fe3O4, a ligand exchange method is used to prepare 4nm superparamagnetic ferroferric oxide nanoparticles DHCA@Fe3O4 in the aqueous phase, which can be used as a 4nm SPIONs contrast agent for T2. The specific steps include the following:

[0085] S6.1: Dissolve DHCA in THF to obtain a mixed solution, heat the mixed solution in an oil bath to 40°C; take the THF solution of OA@Fe3O4 obtained in S5, add it dropwise to the mixed solution to make the mass ratio of DHCA to OA@Fe3O4 be 5:1, and keep warm for 2 hours; S6.1 is performed under magnetic stirring.

[0086] S6.2: The reactants obtained in S6.1 were cooled to room temperature and divided into centrifuge tubes; a small amount of 0.3 mol / L NaOH solution was added to the centrifuge tubes to make the mixed solution weakly alkaline. Then, after centrifugation at a speed of 2000 rpm / min for 20 min, the supernatant was removed and the precipitate in the tube was taken; deionized water was added to the centrifuge tube to dissolve the precipitate, and then ultrasonically dispersed for 60 min to obtain aqueous superparamagnetic ferroferric oxide nanoparticles DHCA@Fe3O4, which can be placed in a refrigerator at 4°C.

[0087] Example 4

[0088] A method for preparing a T2 contrast agent based on 4nm superparamagnetic ferroferric oxide nanoparticles, specifically comprising the following steps:

[0089] Firstly, 4nm superparamagnetic iron oxide nanoparticles OA@Fe3O4 in oil phase were prepared by high temperature pyrolysis method with variable temperature rate.

[0090] S1: Ferrous acetylacetonate, oleic acid, oleylamine, and 1,2-hexadecanediol were dissolved in diphenyl ether at a molar ratio of 1:4:4:7, and mixed evenly under magnetic stirring.

[0091] S2: The mixed solution obtained in S1 is evacuated at room temperature for 120 min, heated to 90°C, and then evacuated for another 10 min; S2 is performed under magnetic stirring.

[0092] S3: turn off the vacuum, fill with nitrogen, and heat the mixed solution obtained in S2 to 150°C at a rate of 0.5°C / min under a nitrogen atmosphere, and keep it warm for 120 minutes; then heat it to 250°C at a rate of 6°C / min, and keep it warm for 20 minutes; S3 is performed under magnetic stirring.

[0093] S4: The reactants obtained in S3 were cooled to room temperature and divided into centrifuge tubes; acetone was added to the centrifuge tubes, and the volume ratio of acetone to reactants was 5:2. After centrifugation at 8500 rpm / min for 10 min, the supernatant was removed and the precipitate in the tube was taken; an appropriate amount of toluene was added to the centrifuge tube to dissolve the precipitate, and the supernatant was poured into a new centrifuge tube after centrifugation at 8500 rpm / min for 10 min.

[0094] S5: Repeat the centrifugal washing process of S4 for 3 times to obtain superparamagnetic iron oxide nanoparticles OA@Fe3O4 in the oil phase, and disperse them in a THF solution. The obtained OA@Fe3O4 THF solution can be placed in a refrigerator for refrigeration.

[0095] S6: Using OA@Fe3O4, a ligand exchange method is used to prepare 4nm superparamagnetic ferroferric oxide nanoparticles DHCA@Fe3O4 in the aqueous phase, which can be used as a 4nm SPIONs contrast agent for T2. The specific steps include the following:

[0096] S6.1: Dissolve DHCA in THF to obtain a mixed solution, heat the mixed solution in an oil bath to 60°C; take the THF solution of OA@Fe3O4 obtained in S5, add it dropwise to the mixed solution to make the mass ratio of DHCA to OA@Fe3O4 be 1:1, and keep warm for 4 hours; S6.1 is performed under magnetic stirring.

[0097] S6.2: The reactants obtained in S6.1 were cooled to room temperature and divided into centrifuge tubes; a small amount of 0.6 mol / L NaOH solution was added to the centrifuge tubes to make the mixed solution weakly alkaline. Then, the mixture was centrifuged at 3000 rpm / min for 10 min, the supernatant was removed, and the precipitate in the tube was taken; deionized water was added to the centrifuge tubes to dissolve the precipitate, and then ultrasonically dispersed for 30 min to obtain aqueous superparamagnetic ferroferric oxide nanoparticles DHCA@Fe3O4, which can be placed in a refrigerator at 4°C.

[0098] Comparative Example

[0099] This comparative example adopts the following steps to prepare a contrast agent based on 4nm paramagnetic ferroferric oxide nanoparticles (PIONs):

[0100] First, 4 nm paramagnetic ferroferric oxide nanoparticles of the oil phase were prepared by high-temperature pyrolysis. Among them, the operations of S1-S5, except S3, were the same as those in Example 1. Specifically, S3 was as follows: the vacuum was turned off and nitrogen was filled in, so that the mixed liquid obtained in S2 was first heated to 200° C. and kept warm for 30 min in a nitrogen atmosphere by using a proportional-integral-differential control method; then, it was heated to 265° C. and kept warm for 30 min by using a proportional-integral-differential control method.

[0101] The morphology of the 4 nm paramagnetic ferroferric oxide nanoparticles of the oil phase prepared in this comparative example is as follows: Figure 8 As shown by Figure 8 It can be seen that the nanoparticles are spherical and evenly dispersed. Fig. 9 As shown in Figure 2, the average particle size of the nanoparticles is 4.03±0.2nm. The crystal structure of the nanoparticles is shown in Figure 2 Fig.10 As shown, it is an inverse spinel structure. Figure 8-Figure 10 , proving that the nanoparticles are 4nm ferroferric oxide.

[0102] S6: Using the prepared 4 nm paramagnetic ferroferric oxide nanoparticles in the oil phase, a ligand exchange method is used to prepare water-phase paramagnetic nanoparticles, i.e., 4 nm PIONs contrast agent. The specific preparation method is the same as in Example 1. The hysteresis loop of the prepared water-phase paramagnetic ferroferric oxide nanoparticles at room temperature is as follows: Fig.11 As shown in , it is a straight line passing through the origin, indicating that the magnetization intensity of the nanoparticle gradually increases with the increase of the magnetic field, but cannot reach saturation; the hysteresis loop of the nanoparticle at 5K is shown in Fig.12 As shown in Figure 2, it is still a straight line. The magnetization intensity of the nanoparticle gradually increases with the increase of the magnetic field, but it cannot reach saturation. The hydrodynamic particle size of the nanoparticle is shown in Figure 2. Fig.13 As shown, it is 7.53±0.37nm. Figure 11-13 , indicating the paramagnetic properties of the nanoparticles prepared in this comparative example.

[0103] Contrast agent performance comparison test:

[0104] The paramagnetic ferroferric oxide nanoparticles obtained in the comparative example 1 and the superparamagnetic ferroferric oxide nanoparticles obtained in the example 1 were subjected to T2-weighted contrast imaging under a 7T magnetic field. The results are as follows: Fig.14 As shown, the R2 relaxation rate is Fig.15 shown.

[0105] Depend on Fig.14 It can be seen that compared with paramagnetic ferroferric oxide nanoparticles, the T2-weighted magnetic resonance image of superparamagnetic ferroferric oxide nanoparticles is significantly darker, indicating that the T2 imaging contrast is significantly enhanced and the imaging sensitivity is high; Fig.15 It can be seen that the molar transverse relaxation rate R2 of the superparamagnetic ferroferric oxide nanoparticles obtained in Example 1 is as high as 201.8 mM -1 s -1 , reaching 11.3 times that of the paramagnetic ferroferric oxide nanoparticles obtained in Comparative Example 1, indicating that the superparamagnetic ferroferric oxide nanoparticles prepared by the method of the present invention have higher saturation magnetization intensity and good dispersion, and can be well used as a T2-weighted contrast agent.

[0106] Those skilled in the art can understand that the above are only preferred examples of the invention and are not intended to limit the invention. Although the invention is described in detail with reference to the above examples, those skilled in the art can still modify the technical solutions recorded in the above examples or replace some of the technical features therein with equivalents. Any modification, equivalent replacement, etc. made within the spirit and principle of the invention shall be included in the protection scope of the invention.

Claims

1. A method for preparing a T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles, characterized in that: The following steps are involved: S1: dissolving ferric acetylacetonate, oleic acid, oleylamine, and 1,2-hexadecanediol in a reducing solvent at a molar ratio of 1:3:3:5 to 1:4:4:7, and mixing them uniformly under magnetic stirring; S2: evacuate the mixed solution obtained in S1 at room temperature, heat it to 60-90° C., and evacuate it again; S2 is performed under magnetic stirring; S3: turn off the vacuum, fill with nitrogen, and heat the mixed solution obtained in S2 to 150-220°C at a rate of 0.5-2.5°C / min under a nitrogen atmosphere, and keep it warm for 20-120min; then heat it to 250-300°C at a rate of 3-10°C / min, and keep it warm for 20-60min; S3 is performed under magnetic stirring; S4: Cool the reactants obtained in S3 to room temperature and dispense them into centrifuge tubes; add ethanol or acetone into the centrifuge tubes to clean the free surfactant in the reactants; after centrifugation, remove the supernatant and take the precipitate in the tube; add a base carrier liquid into the centrifuge tube to dissolve the precipitate, centrifuge again, and pour the obtained supernatant into a new centrifuge tube; S5: Repeat the centrifugal washing process of S4 for multiple times to obtain superparamagnetic iron oxide nanoparticles OA@Fe3O4 in the oil phase, and disperse them in a tetrahydrofuran solution; S6: Using the OA@Fe3O4, a ligand exchange method is used to prepare aqueous superparamagnetic ferrosoferric oxide nanoparticles DHCA@Fe3O4, i.e., a T2 contrast agent.

2. The method for preparing a T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles according to claim 1, characterized in that: The S6 is specifically implemented through the following sub-steps: S6.1: dissolving DHCA in tetrahydrofuran to obtain a mixed solution, heating the mixed solution to 40-60°C; then taking the tetrahydrofuran solution of OA@Fe3O4 obtained in S5, adding it dropwise to the mixed solution to make the mass ratio of DHCA to OA@Fe3O4 be 1:1-5:1, and then keeping the mixture warm for more than 2 hours; S6.1 is performed under magnetic stirring; S6.2: The reactants obtained in S6.1 are cooled to room temperature and divided into centrifuge tubes; NaOH solution is added to the centrifuge tubes to make the mixed solution weakly alkaline; after centrifugation, the supernatant is removed and the precipitate in the tube is taken; deionized water is added to the centrifuge tubes to dissolve the precipitate, and then ultrasonically dispersed to obtain aqueous superparamagnetic ferroferric oxide nanoparticles DHCA@Fe3O4.

3. The method for preparing a T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles according to claim 1, characterized in that: In the above S1, the reducing solvent includes any one of diphenyl ether, dibenzyl ether and octadecene.

4. The method for preparing a T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles according to claim 1, characterized in that: In S4, the base carrier liquid includes any one of cyclohexane, dichloromethane, chloroform and toluene.

5. The method for preparing a T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles according to claim 1, characterized in that: In S4, the volume ratio of ethanol to reactant in the centrifuge tube is 3:2 to 5:2, and the volume ratio of acetone to reactant is 3:2 to 5:

2.

6. The method for preparing a T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles according to claim 1, characterized in that: In S2, the mixed liquid is evacuated at room temperature for 10 to 120 minutes, heated to 60 to 90° C., and then evacuated for another 10 to 120 minutes.

7. The method for preparing a T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles according to claim 1, characterized in that: In S3, the mixed liquid is heated to 180-200°C at a rate of 2-2.5°C / min under a nitrogen atmosphere, and kept warm for 30-60 minutes; then heated to 265-275°C at a rate of 3-5°C / min, and kept warm for 30-45 minutes.

8. The method for preparing a T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles according to claim 1, characterized in that: In the S4, after centrifugation at a speed of 5000-8500 rpm / min for 10-20 min, the precipitate is collected; after adding a base carrier liquid to dissolve the precipitate, the supernatant is collected after centrifugation at a speed of 5000-8500 rpm / min for 10-20 min.

9. The method for preparing a T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles according to claim 2, characterized in that: In the S6.2, the concentration of NaOH is 0.3-0.6 mol / L; during centrifugation, the centrifugation is performed at a speed of 2000-4000 rpm / min for 10-20 min; and the ultrasonic dispersion time is 10-60 min.

10. A T2 contrast agent based on extremely small superparamagnetic ferroferric oxide nanoparticles, characterized in that: The T2 contrast agent is prepared according to the method for preparing extremely small superparamagnetic ferroferric oxide nanoparticles according to any one of claims 1 to 9.